# ESGREV NEWSLETTER

THE OFFICIAL NEWSLETTER OF THE ESCMID STUDY GROUP FOR RESPIRATORY VIRUSES

### In This Issue

- MESSAGE FROM THE EC
- MEMBERSHIP REPORT
- HOW TO JOIN ESGREV (PDF)
- WELCOME NEW SG MEMBERS
- NEW MEMBER SPOTLIGHT
- MEET THE PROFESSOR
- NEWS FROM THE MEMBERS
- ESGREV ANNOUNCEMENTS
- ESGREV WINTER WEBINAR
- ESGREV AT ECCMID 2023
- ESCMID GRANTS & WORKSHOPS

# A MESSAGE FROM THE ESGREV EXECUTIVE COMMITTEE:



As we start to close out 2023, the ESGREV Executive Committee would like to reflect on the accomplishments of our wonderful members and thank you for your contributions that help advance our Study Group missions:

- Bring together the leading experts on respiratory viruses and link existing initiatives, and align research efforts
- Seek scientific consensus on recent scientific data and remaining data gaps
- Drive the development of cross-organizational clinical guideline recommendations on diagnostic testing strategies, antiviral treatments, and vaccines
- Help reduce the burden of respiratory viruses in society through public awareness and educational activities

We also extend an invitation to all of our members and interested members of the community to attend our Winter Webinar this month on the impact of COVID-19 on respiratory viruses. See pg. 4 for registration and details.

Chairperson: Prof. Roy Chemaly, United States Secretary: PD Dr. Chrysanthi Skevaki, Germany

Treasurer: Prof. Barbara Rath, France

Science Officer: Prof. Sotirios Tsiodras, Greece Education Officer: Prof. Louis Bont, Netherlands



Did you miss our last newsletter? Check it out **here**!







### MEMBERSHIP REPORT

We have welcomed 30 new members in 2022 from 13 countries, 18F | 12M. Our new members come from diverse backgrounds, specialties &

Here is a helpful guide to share with your colleagues on How to Join ESGREV Find the PDF here!

How do I join

levels of experience, from students to distinguished professors. Currently, ESGREV has 73 members.

ESCMID requires all study groups to have 90+ members by 2024. To help us reach this goal, we ask that all of our current members extend an invitation to interested colleagues, mentees, or mentors to join





#### **NEW MEMBER SPOTLIGHT**



Dr. Lorenzo Zaffiri MD, **PhD** is a Transplant Pulmonologist with a background in Infectious Diseases and Immunology. He is the Associate Director of

the Lung Transplant Program at Cedars-Sinai in Los Angeles, CA. His research includes understanding the impact of respiratory virus infections on lung transplant recipients and changes in lung immune responses.




Dr. Zaffiri!

Follow him on Twitter @lorenzozaffiri

Welcome to ESGREV,

Our new members in 2022 come from near & far!



### HELP US WELCOME OUR **NEWEST MEMBERS!**

- Dr. Elen Vink (Glasgow, UK)
- Dr. Anne Wyllie (New Haven, CT. US)
- Dr. Caoimhe Brennan (Dublin, Ireland)
- Dr. Georgios Angelidakis (Houston, TX, US)
- Dr. Helle Brander Eriksen (Denmark, Copenhagen)
- Dr. Eduardo Lagarejos Gonzalez (Canary Island, Spain)



### MEET THE PROFESOR



PD Dr. Chrysanthi Skevaki is the Campus and Research Group Leader at the Institute of Laboratory Medicine and Pathobiochemistry, University Hospital Gießen and Marburg, Germany.

PD Dr. Chrysanthi Skevaki is a physician specialist in laboratory medicine, microbiology, virology, and infection epidemiology. She also works as a senior attending physician and leads the Gießen Campus of the Institute of Laboratory Medicine at the University Hospital of Gießen and Marburg, Germany.

Dr. Skevaki is also a Research Group Leader with a strong focus on biomarkers in allergy, as well as on the interrelationship between respiratory viruses and chronic inflammatory lung diseases, such as asthma and COPD.

Her group utilizes in-silico, in-vitro, and inanimal models for their investigations. Dr. Skevaki is also the PI for several clinical studies, and her research projects are funded by the German Research Council (DFG), the German Lung Center (DZL),

#### PD Dr. Chrysanthi Skevaki

the Foundation for Pathobiochemistry and Molecular Diagnostics, and the Rhön Klinikum, among other sources.

Dr. Skevaki serves as a reviewer for numerous journals and grant councils and has published over 90 peer-reviewed articles.

Dr. Skevaki has also served on several positions of the European Academy of Allergy and Clinical Immunology-associated Committees and Task Forces, such as Chair of the Infections and Allergy Interest Group.

Finally, she is the founder of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group on Respiratory Viruses (ESGREV) and an ESCMID fellow.



You can follow PD Dr. Skevaki on Twitter @cskevaki







# NEWS FROM THE MEMBERS

• **ESGREV** would like to hear about your latest updates, like new jobs, promotions, publications, grants, research initiatives, and other big life updates!

 Share your exciting news with us so we can help celebrate our members' accomplishments!








### ESGREV Announcements



nesherke@bgu.ac.il 2li.shafat@gmail.com





PI: Prof. Lior Nesher & Dr. Tali Shafat

**Objective:** To investigate the effect of different anti-CD20 monoclonal antibodies (mAb) agent on COVID-19 clinical course and outcome.

**Invitation to participate**: The project PIs are looking for participating centers where each local PI will be a study investigator. For more information, please e-mail Prof. Lior Nesher and Dr. Tali Shafat.





#### ESGREV Annual Evaluation





ESCMID requires that each study group demonstrates a commitment to academic and collaborative science, and list their achievements in their annual reports.

- WHY IS THIS IMPORTANT? The top 5 study groups with consistently high performance is eligible for the Study Group Excellence Award and a monetary prize.
- **HOW CAN I HELP?** Engage with us on publications, research initiatives, collaborations with other ESCMID study groups, and educational activities that meet ESCMID's requirements.



## ESGREV WINTER WEBINAR

The Interplay of Respiratory Viruses and


**COVID-19:** Re-emergence of Respiratory Viral Seasonality and the New Normal After the Pandemic

WINTER WEBINAR



ESCMID STUDY
GROUP FOR
RESPIRATORY VIRUSES

European Society of Clinical Microbiology and Infectious Diseases



### THURSDAY, NOVEMBER 17

0930-1300 CST | 1630-2000 CET
HOSTED BY THE ESGREV EXECUTIVE COMMITTEE
REGISTER TO RECEIVE A LINK TO OUR WEBINAR



@esgrev\_escmid



Become an ESGREV Member



Register Now



## ESGREV WINTER WEBINAR



Join us by registering at the link below to hear presentations from ESGREV executive committee members and junior members. Topics include hospitalacquired COVID-19 and other respiratory viral infections during the pandemic, respiratory viral co-infections in patients with COVID-19, COVID-19-related changes in RSV epidemiology, the upcoming influenza season and what we can expect, the next generation of COVID-19 immunizations, and the current scientific challenges and lessons from national/global response to COVID-19.



Dr. Amy Spallone



Dr. Paraskevi C. Fragkou



Dr. Annefleur Langedijk



Dr. Maren Alchikh



PD Dr. Chrysanthi Skevaki



Prof. Lior Nesher



Prof. Sotirios Tsiodras



Prof. Roy Chemaly



### ESGREV AT ECCMID 2023



Join us during our **ESGREV sessions at ECCMID 2023!**These special events will highlight the latest research and data on a variety of respiratory viral pathogen topics and their presentations in special populations & host-pathogen interactions.

#### Workshop

Immunology & vaccinology

SESGREV, ESGMYC, EFISG

#### Title: Host-pathogen interactions and immunotherapies in infectious diseases

- A framework for understanding host-pathogen interactions in infectious diseases
  - Liise-Anne Pirofski (United States)
- Host-pathogen interactions and immunotherapy in mycobacterial infections
  - Reinout van Crevel (Netherlands)
- Immune dysregulation and immunotherapy for fungal infections
  - Michail S. Lionakis (United States)

SAVE THE DATE:

Submit your abstracts to ECCMID 2023

Oct 17 - Nov 30

#### **Symposium**

Viral infection & disease

SESGREV, ISIRV

#### Title: Tackling influenza and RSV management in the post-COVID-19 era


- Differences in the clinical presentation and outcomes of respiratory viral infection at extreme of ages
  - Virginie Prendki (Switzerland)
- The impact of diagnostics on the timeliness of antiviral treatment of influenza, RSV, and COVID-19
  - Giulia DeAngelis (Italy)
- From the clinical trials to clinic practice: the evolution of management of COVID-19, RSV, and influenza in North America
  - Nelson Lee (Canada)
- Treatment or prevention? Global and public health perspectives of guideline development for respiratory viruses
  - Sylvie Van Der Werf (France)





### ECCMID 2023 Outreach Grant applications now open

ESCMID is proud to continue the ECCMID Outreach Grant once again for ECCMID 2023. This grant is aimed at supporting and promoting ECCMID participation from persons residing in Low- and Lower-middle income countries. The call to apply is now open! Learn more and see the NEW eligibility criteria on the ESCMID website.



#### Check out ESCMID courses for 2023!

ESCMID already has a number of postgraduate courses open for registration for 2023! Get a head start on planning out your educational content for next year by visiting the ESCMID website and checking out the course flyers there.



Read more <u>here</u>



ESCMID STUDY GROUP FOR RESPIRATORY VIRUSES